OBJECTIVE： To investigate therapeutic efficacy， safety and economics of budesonide for infant bronchiolitis based on salbutamot. METHODS： In prospective study， 160 inpatient children with bronchiolitis during Oct. 2014-Apr. 2016 were divided into observation group and control group according to admission order， with 80 cases in each group. Both groups received conventional treatments. Control group was given Salbutamol solution for inhalation 0.25 mL added into 0.9％ Sodium chloride injection 3 mL， q8 h. Observation group was given Budesonide suspension for inhalation 2 mL added into 0.9％ Sodium chloride injection 1 mL+Salbutamol solution for inhalation 0.25 mL， q8 h. Both groups received oxygen driven inhalation， and treated for 5-7 d. Clinical symptom disappearance time， hospitalization time and clinical efficacy were compared between 2 groups as well as therapy drug cost （aerosol inhalation， other therapy drugs）. The occurrence of ADR was recorded.  RESULTS： There was no statistical significance in cough disappearance time， wheezing disappearance time， lung rale disappearance time， tri-retraction sign disappearance time and hospitalization time between 2 groups （P＞0.05）. There was no statistical significance in total response rate between observation group （95.00％） and control group （92.50％） （P＞0.05）. The cost of inhalation drugs in observation group [（355.77±10.98）yuan] was significantly higher than control group [（26.83±2.86）yuan]， with statistical significance （P＜0.05）. There was no statistical significance in the cost of routine therapy drugs between 2 groups （P＞0.05）. There was no significant ADR between 2 groups during treatment. CONCLUSIONS： For infant bronchiolitis， aerosol inhalation of budesonide based on salbutamol sulfate can not significantly shorten disease， shorten hospitalization time and improve clinical efficacy， but increase therapy cost.